Abstract
Keller and Gunther show that Wnt-driven mammary cancers challenged with simulated targeted therapy (Wnt withdrawal) undergo clonal evolution, which stringently selects for mutations that restore a “just right” level of oncogenic signaling. Therefore, cancer relapses emerge from rare subclones that are encumbered by an untapped vulnerability to oncogene overdose.
Original language | English (US) |
---|---|
Pages (from-to) | 893-905.e4 |
Journal | Cell Reports |
Volume | 26 |
Issue number | 4 |
DOIs | |
State | Published - Jan 22 2019 |
All Science Journal Classification (ASJC) codes
- General Biochemistry, Genetics and Molecular Biology